Regional and supply-chain research

Industrial Solvents Reagents High Purity Chemicals Keyword Candidate Study

Industrial Solvents Reagents High Purity Chemicals Keyword Candidate Study. A dated 46-record cohort study compares composition, parent sets and evidence coverage. Comparative structure study; archive date 2026-10-16.

Revision and archive snapshot: 2026-10-16

Swipe tables sideways to see all columns.

Research findings

Comparative structure study

The largest recorded reporting jurisdiction, Shanghai, contains 7 records (15.2% of this 46-record cohort). The remaining cohort contains 39 records. The comparison concerns archive composition.

The recorded industry label Biomedicine accounts for 47.8% here (22/46), compared with 8.9% in the parent set (1,721/19,297), an absolute gap of 38.9 percentage points.

19/46 companies link to pages with existing source-supported excerpts (41.3% of the cohort). The other 27 records remain usable for archive composition, but do not support new operating case studies.

3 keyword candidates match only a company name, with no matching term in recorded products or sub-industry fields. Product evidence is needed before treating these as operating businesses in this segment.

Company cohortDirectly linked pagesShare of public archiveArchive date
46460.2%2026-10-16

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

Comparable sets and compositional differences

The parent set, All public archive records, contains 19,297 records. This cohort contributes 46 (0.2%); 19,251 records remain after excluding it.

CategoryCohort count/baseReference: All public archive recordsGap (pp)Representation ratioRest count/base
industry · Biomedicine22/46 · 47.8%1,721/19,297 · 8.9%+38.95.361,699/19,251
chain role · Biomedicine and medical devices / Complete systems and use-case applications20/46 · 43.5%1,373/19,297 · 7.1%+36.46.111,353/19,251
chain role · Fine chemicals / Basic and process materials14/46 · 30.4%740/19,297 · 3.8%+26.67.94726/19,251
industry · Advanced chemicals8/46 · 17.4%269/19,297 · 1.4%+16.012.48261/19,251
sub-industry · In vitro diagnostics7/46 · 15.2%32/19,297 · 0.2%+15.191.7725/19,251
sub-industry · Medical devices and health equipment5/46 · 10.9%87/19,297 · 0.5%+10.424.1182/19,251
reporting jurisdiction · Shanghai7/46 · 15.2%1,131/19,297 · 5.9%+9.42.601,124/19,251
reporting jurisdiction · Hunan5/46 · 10.9%667/19,297 · 3.5%+7.43.14662/19,251
industry · Advanced materials5/46 · 10.9%3,381/19,297 · 17.5%-6.70.623,376/19,251
reporting jurisdiction · Shenzhen5/46 · 10.9%1,398/19,297 · 7.2%+3.61.501,393/19,251

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded industry label Biomedicine covers 1,699/19,251 remaining records (8.8%), an absolute gap of 39.0 percentage points from this cohort.

Concentration and cross-sectional structure

The full reporting jurisdiction distribution has 15 labels; the top 3 contain 19/46 records (41.3%).Other known labels contain 27 records.

For 46 records with known labels, the effective category count is 10.5, versus 15 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 5 others are included in the calculations above.

Recorded labelRecordsShare of cohort
Shanghai715.2%
Jiangsu715.2%
Shenzhen510.9%
Hunan510.9%
Beijing48.7%
Guangdong36.5%
Zhejiang36.5%
Sichuan24.3%
Tianjin24.3%
Anhui24.3%

Record counts do not rank supply capability or economic size.

The largest intersection, Beijing × Biomedicine, contains 4 records, or 100.0% of the 4 records carrying the Beijing label.

reporting jurisdictionindustryIntersection recordsCohort share
BeijingBiomedicine48.7%
ShenzhenBiomedicine48.7%
ShanghaiBiomedicine36.5%
HunanBiomedicine36.5%
ShanghaiEnergy conservation and environmental protection24.3%
SichuanBiomedicine24.3%
JiangsuAdvanced materials24.3%
ZhejiangAdvanced materials24.3%

A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.

This page displays 8 of the full cross-tab’s 32 non-empty cells; the other 24 remain in the analysis.

Evidence coverage and strength of conclusions

Record fieldNon-empty/cohortCompletion
Company name46/46100.0%
reporting jurisdiction46/46100.0%
industry46/46100.0%
Recorded products46/46100.0%
sub-industry46/46100.0%
Chain labels46/46100.0%

Non-empty fields are not necessarily accurate or supported by originals.

Scope of source supportCount
Profiles with source-supported excerpts19
Distinct corresponding companies19
Reviewed Chinese/English paragraph pairs20

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

Transparent rule reminderRecordsCohort share
Contains registration-narrative wording24.3%

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

Matched fieldCandidatesCohort share
Company name510.9%
Recorded products3780.4%
Sub-industry1226.1%

An ID may match several fields, so counts may exceed the cohort total. Matches establish search relevance only.

Among the translated non-broad query terms, “reagents” has the most matches: 38/46. Name, product and sub-industry fields match 2, 29 and 11 records respectively; the largest field is product field. Fields can overlap, and a term remains a search link rather than verified business activity.

Selected query termCandidates/shareName matchesProduct fieldSub-industry
reagents38 · 82.6%22911

Selected broad terms and specific segment terms, not the full query. Terms and fields can overlap and must not be summed. Counts show lexical sensitivity; no records are removed without primary evidence.

3 candidates match only a name, or lose all product-field matches after the full company name is removed while sub-industry also has no hit. This transparent string test locates copied company descriptions; it does not establish that a company does not operate the business.

Intersection with 2026 local lists

20 of this cohort’s 46 records link through existing company-ID mappings to 2026 lists from all jurisdictions (43.5%). This intersection measures list linkage, not successful recognition or company growth.

Observation setList recordsNew-applicant recordsReview recordsMapped company IDs
National list records linked to this cohort’s IDs2002020

List rows and company IDs are separate counts, not new firms or final recognition.

Stored 2026 local-recommendation records, sources and stage definitions

Recorded roles and delivery checks

Intermediates and high-purity products need scale-up checks

The General-purpose fine chemicals label covers 4 records (8.7% of this cohort). This archive clue raises a verification question about Defined chemicals with process and pilot documents; it does not establish that these companies already deliver it.

Delivery framework, stages and original sources

Related studies and shared records

Shared records with Poct Biosensor Diagnostics Keyword Candidate Study: 12; records in this cohort but outside that set: 34. The intersection/union ratio is 25.5%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with IVD Reagents Bio Testing Keyword Candidate Study: 16; records in this cohort but outside that set: 30. The intersection/union ratio is 21.1%, a measure of label overlap rather than business collaboration. Read comparison

Company samples and record links

CompanyJurisdictionRecorded industry
Shanghai Taiyang Technology Co., Ltd.ShanghaiNext-generation information technology
Shenzhen Lifotronic Technology Co., Ltd.ShenzhenBiomedicine
Beijing Qicarbon Biotechnology Co., Ltd.SichuanBiomedicine
Hunan Runkun Pharmaceutical Co., Ltd.HunanBiomedicine
Shanghai Macklin Biochemical Co., Ltd.ShanghaiBiomedicine
Guangzhou LBP Medicine Science & Technology Co., Ltd.GuangdongBiomedicine
Shenzhen Bioeasy Biotechnology Co., Ltd.ShenzhenBiomedicine
Jiangsu HUAOU Glass Co., Ltd.JiangsuAdvanced materials

Stable-ID samples, not rankings; metrics use the full cohort.

Directly related profiles and reports

Methodology

Read ID deduplication, comparison, batch and evidence definitions